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Abstract
Cytotoxic T-lymphocyte associated protein 4 (CTLA4) is a negative regulator of T-cell proliferation. Polymorphisms in CTLA4
have been inconsistently associated with susceptibility to rheumatoid arthritis (RA) in populations of European ancestry but
have not been examined in African Americans. The prevalence of RA in most populations of European and Asian ancestry is
,1.0%; RA is purportedly less common in black Africans, with little known about its prevalence in African Americans. We
sought to determine if CTLA4 polymorphisms are associated with RA in African Americans. We performed a 2-stage analysis
of 12 haplotype tagging single nucleotide polymorphisms (SNPs) across CTLA4 in a total of 505 African American RA
patients and 712 African American controls using Illumina and TaqMan platforms. The minor allele (G) of the rs231778 SNP
was 0.054 in RA patients, compared to 0.209 in controls (4.462610
226, Fisher’s exact). The presence of the G allele was
associated with a substantially reduced odds ratio (OR) of having RA (AG+GG genotypes vs. AA genotype, OR 0.19, 95% CI:
0.13–0.26, p=2.4610
228, Fisher’s exact), suggesting a protective effect. This SNP is polymorphic in the African population
(minor allele frequency [MAF] 0.09 in the Yoruba population), but is very rare in other groups (MAF=0.002 in 530 Caucasians
genotyped for this study). Markers associated with RA in populations of European ancestry (rs3087243 [+60C/T] and
rs231775 [+49A/G]) were not replicated in African Americans. We found no confounding of association for rs231778 after
stratifying for the HLA-DRB1 shared epitope, presence of anti-cyclic citrullinated peptide antibody, or degree of admixture
from the European population. An African ancestry-specific genetic variant of CTLA4 appears to be associated with
protection from RA in African Americans. This finding may explain, in part, the relatively low prevalence of RA in black
African populations.
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Introduction
Cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152)
is a negative regulator of T-cell activation. As the T-cell activation
signal propagates due to costimulatory B7 molecule (CD80, CD86)
binding of CD28, cell surface expression of CTLA4 increases to
compete with CD28 [1]. CTLA4 also prevents further clonal
expansion of effector T-cells, including regulatory T cells (Treg)
[2,3], and can inhibit osteoclast formation [4].
Genetic variation in CTLA4 (Chromosome 2q33) could
contribute to unchecked T cell or osteoclast activation with
resultant onset of autoimmune disease such as rheumatoid arthritis
(RA). CTLA4 was modestly associated with RA in a recent genome
wide association study (GWAS) of RA in Caucasians [5]. CTLA4
single nucleotide polymorphisms (SNP), such as rs231775 (+49A/
G), have been associated with multiple autoimmune conditions
including RA, Addison’s disease, autoimmune pancreatitis [6],
autoimmune thyroid disease, celiac disease, chronic inflammatory
arthritis [7]. multiple sclerosis [8], type I diabetes mellitus,
Sjo ¨gren’s syndrome [9], and systemic lupus erythematosus (SLE)
[10]. An association with another SNP, rs3087243 (+60C/T), and
RA was found in a Chinese Han population [11]; however, these
results were not replicated in Irish [7], United States Caucasian
[12], or, when corrected for multiple testing, British Caucasian
[13] populations. Analysis of a much larger group of Caucasians
from North America and Sweden associated this marker with RA
[particularly with the anti-cyclic citrullinated peptide (anti-CCP)
antibody positive RA subset] [14]. Given the association of CTLA4
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characterize the genetic contribution of CTLA4 to RA in African
Americans – a population not yet explored.
RA is purported to be less prevalent in African Americans than
in Caucasians based on clinical observation and data in black
continental Africans [15–19]. African-specific protective alleles
might explain the lower disease prevalence among persons of
African ancestry and should be evaluated in genetic studies with
this population.
In this study, we genotyped CTLA4 haplotype tagging SNPs
(htSNPs) in two groups totaling 505 African American patients
with RA and 712 African American healthy controls. We found
and replicated a novel protective association at an ethnic-specific
intronic SNP, rs231778, in both independent groups. While this
SNP is polymorphic only in the HapMap Yoruba population, we
confirmed a lack of variation by genotyping 530 Caucasians.
Importantly, we did not detect significant confounding for
association of rs231778 when our patients were stratified by level
of European admixture or by RA subclassification such as
presence of the HLA-DRB1 shared epitope (SE) or anti-cyclic
citrullinated peptide (anti-CCP) antibodies [20]. We also did not
find association with two SNPs (rs3087243 and rs231775)
previously reported to have disease associations with RA in
European ancestry populations or with other autoimmune
diseases.
Our data reveal a protective African ancestry-specific allele that
may contribute to the purportedly lower prevalence of RA in
persons of African ancestry and provide suggestions for future
research into the relationship between T cell regulation and RA
pathogenesis.
Methods
The Consortium for the Longitudinal Evaluation of African
Americans with Early Rheumatoid Arthritis (CLEAR) Registry
enrolled self-identified African Americans with RA who met the
American College of Rheumatology (ACR) 1987 diagnostic
criteria [21]. Participants for CLEAR were recruited from the
University of Alabama at Birmingham (UAB) [coordinating
center]; Emory University/Grady Hospital (Atlanta, GA); Uni-
versity of North Carolina at Chapel Hill; Medical University of
South Carolina (Charleston, SC); and Washington University (St.
Louis, MO). Recruitment occurred in two phases: enrollment of
patients with early RA (,2 year disease duration) followed
longitudinally until 5 years disease duration, from 2000 to 2007
(CLEAR I); and enrollment of patients with RA of any duration
from the same sites as part of a cross-sectional analysis from 2007
to present (CLEAR II). Comprehensive demographic, clinical, and
radiographic data are being collected on all CLEAR participants,
and serum and DNA samples are being stored [22]. These data
allow for stratification of RA patients [20] by presence of the HLA-
DRB1 SE and anti-CCP antibody positivity. We have also
measured estimated global admixture using a panel of ancestry
informative markers (AIMs), as previously reported [23]. A group
of healthy African American controls, for the longitudinal arm of
this study, with similar sex, age, and geographic location has been
recruited, as previously described [23]. All participants were
recruited with informed consent under the approval of each
respective Institutional Review Board. Genomic DNA was isolated
using standard methods and stored at 270uC.
This study included 282 African American RA patients and 149
African American controls from the CLEAR longitudinal study
(CLEAR I) and 223 African American RA patients from the
CLEAR cross-sectional study (CLEAR II). We also obtained DNA
samples from an additional 563 healthy African Americans from
Alabama recruited for a case-control study of SLE [24] to use as
controls for the CLEAR II RA patients. Demographics for
CLEAR I and CLEAR II RA patients are presented in Table 1.
Controls were younger than the RA patients (mean age: CLEAR
I=45614 years, CLEAR II=35611 years). Similar to the
patient groups, both of the control sets were predominantly
female (percent female: CLEAR I=82%, CLEAR II=74%). In
total, we analyzed 505 African American RA patients and 712
African American controls. We used RA patients and controls
from CLEAR I as an initial test set and RA patients from the
CLEAR II and additional Alabama controls as a replication
group.
All SNPs within the CTLA4 region (62 kb) that have a minor
allele frequency (MAF) $0.05 in the Yoruba HapMap population
(Phase II/Release 21) were genotyped: rs231775, rs231776,
rs231777, rs231778, rs231779, and rs3087243. Data from the
resequencing of CTLA4 in both African and European populations
contracted to SeattleSNP (Dr. Debbie Nickerson, University of
Washington) were kindly provided from the Population Genetics
Study coordinated at UAB (Drs. Richard Kaslow and Robert
Kimberly). CTLA4 SNPs detected by SeattleSNP that capture
information on polymorphisms not present in HapMap for
Africans with a MAF $0.05 were additionally genotyped:
rs11571319, rs231772, rs231780, rs34031880, rs733618, and
*5251. *5251 is not yet listed in dbSNP: its physical location is
54945227 in NCBI contig file NT_005403, and its surrounding
sequence is ATGGTAGCCTTGCTTATTGT [G/T]
GGTGGCAACCTTAATAGCAT.
Genotyping was performed by the Illumina FastTrack Gold-
enGate BeadXpress genotyping service (San Diego, CA) for
CLEAR I for SNPs from the International HapMap Consortium.
All other genotyping was performed using Applied Biosystems
TaqMan Allelic Discrimination Assays (Foster City, CA) on an
ABI 7900HT Genetic Analyzer. Overall, between both platforms
for all SNPs, our genotyping success rate was 99.4%. We
successfully genotyped rs231778 among 74 samples using both
platforms with 100% reproducibility. To confirm the monomor-
phic nature of rs231778, we genotyped this SNP in 530 Caucasian
Author Summary
Rheumatoid arthritis (RA) is a systemic autoimmune
condition affecting the synovial membranes of diarthrodial
joints. The etiology of RA is unclear but is thought to result
from an environmental trigger in the context of genetic
predisposition. We report that a single nucleotide poly-
morphism (SNP) (rs231778) in CTLA4, which encodes a
negative regulator of T cell activation, is associated
(p=2.4610
228) with protection from developing RA
among African Americans. rs231778 is only polymorphic
in populations of African ancestry. Protective alleles such
as this one may contribute to the purported lower
prevalence of RA in African Americans. Our finding appears
to be independent from confounding by linkage with the
HLA-DRB1 shared epitope or by genetic admixture.
Furthermore, we did not replicate associations of CTLA4
SNPs with RA or other autoimmune diseases previously
reported in Asians and Caucasians, such as rs3087243
(+60C/T) and rs231775 (+49A/G). The associations of
different SNPs with RA susceptibility specific to different
populations highlight the importance of CTLA4 in the
pathogenesis of RA and demonstrate the ethnic-specific
genetic background that contributes to its susceptibility.
CTLA4 SNP Associated with Protection from RA
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toid Arthritis (TEAR) study.
Fisher’s exact tests were performed on SAS 9.0 (Cary, NC) and
exact logistic regression tests performed on LogXact 8.0 (Cam-
bridge, MA). We controlled for potential confounding by HLA-
DRB1 status, anti-CCP antibody positivity, and genetic admixture
following the approach of Redden et al. [25]. Linkage Disequi-
librium and haplotype analyses were performed with HaploView
v3.31 [26]. All SNPs were in Hardy-Weinberg Equilibrium (tested
with Chi squared tests), except rs231776 (HWE p=0.0085), which
was excluded from further analysis.
Results
Resequencing and Description of Genetic Variation in
CTLA4
Data available from the International Haplotype Mapping
Consortium (HapMap), as accessed in February 2008, appear
incomplete with regard to coverage of CTLA4. Only SNPs present
from the 59 region through intron 1 (rs231775, rs231776,
rs231777, rs231778, rs231779) are represented with detailed
genotyping data. HapMap does not provide data for SNPs among
the remaining exons and introns of CTLA4 but does present
information for polymorphisms in the 39 end of the gene, such as
rs3807243. To select htSNPs that cover the remaining interior
portions of this gene, we accessed resequencing data available
from SeattleSNP that provided detailed genotypes on YRI and
CEU populations. SeattleSNP routinely resequences only 500
basepairs into each end of a given intron. A portion of intron 1 (the
longest intron) is the only region of CTLA4 not completely
resequenced by SeattleSNP; however, intron 1 was completely
covered by HapMap, allowing the combination of these two
resources to provide the most detailed haplotype tagging strategy
for this gene. See Figure 1.
Due to the limited public information on CTLA4 in African
Americans, we used HaploView to calculate linkage disequilibri-
um (LD) across all genotyped SNPs. A plot representing the LD (r
2
values) of SNPs is included as Figure 2.
Association of rs231778 with Rheumatoid Arthritis in
African Americans
We detected a protective effect for RA in African Americans
with the G allele of rs231778 in both CLEAR study groups
(longitudinal and cross-sectional) independently and together
(CLEAR I and CLEAR II combined Fisher’s exact
p=4.46610
226). See Table 2. Because homozygotes for the G
allele were rare, we compared the frequency of persons with
genotypes GG and AG to those with genotype AA. From the odds
ratios of the two groups combined, it can be seen that the presence
of the G allele confers a protective effect (OR=0.19, 95% CI:
0.13–0.26, p=2.4610
228, Fisher’s exact). See Table 3. rs231778 is
not in LD with any other SNP, which suggests any genetic effect it
confers is likely independent. See Figure 2.
The G allele of rs231778 is relatively specific for African
populations as only the A allele is detected among Asians and
Caucasians genotyped in the International HapMap Project and
in Caucasians genotyped by SeattleSNP. Since variation at
rs231778 was not found in the HapMap (n=24) or Perlegen
Table 1. Demographics of populations used in this study.
CLEAR I (Longitudinal) [n=282] CLEAR II (Cross-Sectional)[n=223] P value
Age at onset, average (6SD) 55.6 (613.3) 57.5 (611.2) NS
% Female 82.2 86.3 NS
Disease Duration (yrs), mean (6SD) 1.6 (60.6) 5.9 (61.6) ,0.0001*
Rheumatoid Factor Positive 72.8 80.3 NS
Anti-CCP Antibody Positive 62.0 60.8 NS
% HLA-DRB1 Shared Epitope Positive 42.7 39.2 NS
Anti-CCP – anti-cyclic citrullinated peptide; SD – standard deviation; NS – not significant. * Inclusion criteria were ,2 years disease duration for CLEAR I and any disease
duration for CLEAR II.
doi:10.1371/journal.pgen.1000424.t001
Figure 1. Only SNPs genotyped in this study are listed by name. SNPs in linkage disequilibrium with SNPs genotyped in this study are shown
in brown. SNPs in gray were not genotyped or haplotype tagged due to low minor allele frequency (MAF). SNP - Single Nucleotide Polymorphism.
5251* is not yet registered in dbSNP as described in the methods.
doi:10.1371/journal.pgen.1000424.g001
CTLA4 SNP Associated with Protection from RA
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self-identified Caucasians to assess ethnic specific variation at this
site. Among these 530 subjects, only 3 were heterozygous at
rs231778, and none were homozygous for the G allele, which
yields a MAF of 0.0028. In the 697 healthy African American
individuals we genotyped, the MAF is 0.209 illustrating the ethnic
specificity of this marker.
Since the presence of the SE has been associated with
susceptibility to RA in our population [23] and known to
confound association with RA at other immunologically relevant
loci such as PTPN22 [27], we evaluated our findings in CTLA4 for
possible confounding by the HLA-DRB1 SE, the strongest known
genetic risk factor for RA. We found that the MAF of rs231778
was not different within cases or controls when stratified for
number of SE alleles present. Because only 4 control samples have
two SE alleles, we cannot rule out any possible influence of the SE
on the genetic contribution of CTLA4 in RA susceptibility, but it
appears to be unlikely. See Table 4.
Figure 2. This plot, generated from HaploView v3.31 (Broad Institute), shows the r
2 values between SNPs genotyped in CTLA4.
Darker boxes represent stronger r
2 values. 5251* is not yet registered in dbSNP as described in the methods.
doi:10.1371/journal.pgen.1000424.g002
Table 2. Association with rheumatoid arthritis at rs231778 in African Americans.
Genotype AA AG GG All Fisher’s Exact P value
Longitudinal RA 249 (0.90) 25 (0.09) 2 (0.01) 276 1.572610
28
Controls 99 (0.67) 44 (0.30) 4 (0.03) 147
Cross-sectional RA 186 (0.89) 21 (0.10) 1 (0.01) 208 5.093610
214
Controls 324 (0.59) 202 (0.37) 24 (0.04) 550
Combined RA 435 (0.90) 46 (0.10) 3 (0.01) 484 4.462610
226
Controls 433 (0.62) 236 (0.34) 28 (0.04) 697
Values indicate number of samples with allele frequency in parentheses. Analysis compares number of patients and controls for each genotype (AA vs AG vs GG) in a
362 Fisher’s exact test.
doi:10.1371/journal.pgen.1000424.t002
CTLA4 SNP Associated with Protection from RA
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known recent population admixture [28], we assessed percentage
of European admixture as a confounding factor in the association
of RA with rs231778. Data from a genome-wide admixture panel
performed at the Broad Institute from our previously reported
work [23] allowed calculations of global admixture estimates
(percent European ancestry) for 282 cases and 94 controls (total
N=366). Of these 366 with admixture data, there was successful
genotyping for the CTLA4-containing region of Chromosome 2 in
266 cases and 81 control samples (total N=347). We show the
mean percentage of European ancestry segregated by genotype for
cases and controls in Table 5. The degree of admixture was not
associated with rs231778 genotype (Fisher’s exact p=0.2367). We
confirmed that admixture difference between cases and controls
was not significant using the robust Welch test, which produced a
value of 2.308 (degrees of freedom=215.578, p=0.130).
We did not find a significant association with RA of the G allele
among the 347 samples with complete admixture data and
CTLA4 genotypes (asymptotic p=0.0674); we suspect that this is
due to the reduced statistical power of analysis of a smaller
number of subjects and controls. When we based calculations
upon the 366 samples used in our previous admixture-based
manuscript [23], this small increase in sample size regained
statistical significance of association with RA (asymptotic
p=0.0183). To illustrate further the lack of significance among
t h e3 4 7s a m p l e si sd u et ol a c ko fp o w e r ,f r e q u e n c yc o u n t so f
genotypes among the 366 samples are incorporated in Table 5 to
demonstrate a similar pattern of genotype distributions with and
without these additional samples.
Lack of Genetic Associations with RA at Other CTLA4 Loci
Nonsynonymous SNPs previously associated in other popula-
tions and autoimmune phenotypes (rs3087243 and rs231775) were
not associated with RA in our study. See Table 6. We also found
no association when we analyzed data based upon deduced
haplotypes or at any individual SNP when stratified by RA
subclassification (SE status, anti-CCP antibody status, or percent
European ancestry) as has been observed with RA associations at
other sites in the genome [23] and with CTLA4 SNPs in Caucasian
populations [14]. See Table 6.
We found no significant association with the G allele of
rs3087243, even when stratified for presence of anti-CCP
antibody, as previously reported in Europeans with RA [14]; the
distribution of genotypes and allele frequencies of this SNP were
similar in anti-CCP antibody-positive and anti-CCP antibody-
negative RA patients. Similarly, we found no significant
differences in allele frequency between anti-CCP positive RA
patients and anti-CCP negative RA patients at the SNP associated
with RA in our study (rs231778).
In the initial analysis of the CLEAR longitudinal arm, we found
a protective effect (lower allele frequency in patients than controls)
of the minor allele (G) of rs231780 allele (Fisher’s Exact
p=0.0123). However, upon replication in the CLEAR cross-
sectional arm, this difference in MAF between cases and controls
was not significant in the cross-sectional arm or in both arms
combined [Fisher’s exact p=0.0667; MAF 0.097 in patients, 0.124
in controls]. See Table 6. Of note, the rs231780 SNP appears to
be African-ancestry specific as well, with a MAF of 0.17 in
Africans and ,0.00 in Europeans among HapMap subjects. It is
possible that our lack of association at this marker is due to a true
negative state or due to lack of power for detecting a positive
association, as our the p value is bordering on significance
(p=0.07). Although rs231780 is also an ethnic-specific SNP, there
is not significant LD between it and the strongly associated SNP
rs231778 (r
2=0.107, D9=0.445). The lack of association of the
African-specific SNP, rs231780, with RA might be sufficient to
rule out genetic admixture as the cause of the association at
rs231778.
We also found an association with rs231776 (Fisher’s exact
p=0.0418) when both study groups were combined; however, this
SNP was not in Hardy-Weinberg equilibrium (HWE p=0.0085),
complicating interpretation of these results.
Table 3. Odds ratios for the protective effect of the rs231778
G allele in African Americans with RA.
OR 95% CI Fisher’s Exact P value
Longitudinal 0.23 0.13–0.39 2.127610
28
Cross-sectional 0.17 0.10–0.28 3.354610
217
Combined 0.19 0.13–0.26 2.437610
228
Analysis compares number of patients and controls for genotype AA vs those
with either AG or GG in a 262 Fisher’s exact test. OR – odds ratio; CI –
confidence interval.
doi:10.1371/journal.pgen.1000424.t003
Table 4. Minor allele frequency (MAF) of rs231778
segregated by HLA-DRB1 shared epitope status.
0 SE Alleles 1 SE Alleles 2 SE Alleles Total
Patients 0.05 (N=12/274) 0.06 (N=9/160) 0.06 (N=2/34) 0.05
Controls 0.21 (N=27/130) 0.21 (N=8/38) 0.25 (N=1/4) 0.21
This table combines samples from both CLEAR I and CLEAR II and only
incorporates data where HLA-DRB1 shared epitope (SE) status has been
determined. The ‘N’ listed below each MAF represents the number of ‘G’ alleles
over the total number of alleles for each number of SE alleles present. SE – HLA-
DRB1 shared epitope.
doi:10.1371/journal.pgen.1000424.t004
Table 5. Mean percentage of European ancestry segregated by genotype of rs231778.
Genotype AA AG or GG AA, AG, or GG
Case 0.172 (0.0997) N=240 [246] 0.114 (0.062) N=26 [27] 0.166 (0.098) N=266 [273]
Control 0.146 (0.052) N=67 [75] 0.169 (0.078) N=14 [18] 0.150 (0.057) N=81 [93]
Total 0.166 (0.092) N=307 [321] 0.133 (0.072) N=40 [45] 0.162 (0.090) N=347 [366]
This table provides data for the 347 samples with complete admixture and rs231778 genotyping data. Standard error is provided in parenthesis. Brackets indicate
frequency counts used in determining association of the rs231778 G allele with rheumatoid arthritis among 366 samples, as described in the text.
doi:10.1371/journal.pgen.1000424.t005
CTLA4 SNP Associated with Protection from RA
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We detected a significant novel genetic association with RA in
African Americans at the CTLA4 SNP rs231778. In this case-
control study, African Americans with at least one minor (G) allele
were 0.19 times as likely to have RA as those without a minor
allele (95% CI 0.13 0.26, Fisher’s Exact p=2.437610
228). This P
value does not appear to be subject to the inaccuracy introduced
by cancellation error by complementation [29]. Our study is
limited in sample size due to its exclusive focus on a minority
population, which may introduce influence by bias in sample
collection, genotyping errors, and lack of power. However, due to
our efforts in matching patients and controls and validating our
genotyping results (100% reproducibility in 74 samples on
different genotyping platforms), we believe such biases have been
minimized. We believe that our study is sufficiently powered to
detect associations as we found a statistically significant result in
two separate arms of the study.
The associated SNP, rs231778, is located in intron 1 and is not
in LD with any genotyped SNP in CTLA4 such as the disease-
associated rs3087243 and rs231775 markers. See Figures 1 and 2.
It is possible, however, that LD could span farther than assessed in
this study allowing the possibility that rs231778 is a surrogate
marker for another associated polymorphism well outside of the
gene boundaries of CTLA4. LD has been shown to span several
megabases in African Americans, which supports this possibility
[30]. Additional genotyping of 5–10 AIMs in this chromosomal
region in a large number of African Americans may allow a better
understanding of the long-range haplotype structure. Our study
did include five African-specific SNPs (rs231772, rs231776,
rs231780, rs34031880, 5251*) and one AIM, defined as a
difference in MAF .0.20 between populations, (rs3087243) that
did not associate with RA. The association of the African-specific
allele of rs231778 and RA and the lack of association at these
ethnic-specific markers supports the idea that the association of
rs231778 is independent from bias by genetic admixture.
Interestingly, rs231778 is monomorphic in both Asian and
Caucasian populations, according to genotype data from
HapMap and SeattleSNP, and virtually absent in our genotyping
of 530 Caucasians. Given the ethnic-specific status of this SNP, it is
possible that our finding helps to explain the purported, but as yet
unproven, observation of a lower prevalence of RA in African
Americans compared to Caucasians. We would anticipate the
association of such African-specific protective alleles with resistance
to RA. Racial or ethnic differences have now been suggested in the
association of RA with several genes, including PTPN22 [31],
PADI4 [32], SLC22A4 and RUNX1 [33], and in CTLA4, particularly
between Asian and Caucasian populations [10,34]. These data
highlight the need for additional research into the genetic
background of RA in various populations such as African
Americans to uncover additional ethnic-specific associations.
Our study included 697 healthy African American controls that
possessed a MAF of 0.209 at rs231778. This finding is surprising
since public resources such as the International HapMap
Consortium has a MAF of 0.09 in their panel of 60 Yorubans
and 0.00 in 60 Caucasians. African Americans are considered to
be an admixed population with an African background and
contribution of approximately 20% European genetic ancestry. In
fact, we calculated that European ancestry contributes 1565% of
the genetic composition of African Americans in the CLEAR
study. Therefore, we would expect a MAF for rs231778 to be
between 0.00 and 0.09. Given that our participants were collected
at multiple centers across the Southeastern United States (with
each center having similar MAFs), that we genotyped 74 samples
with 100% reproducibility on dual platforms (TaqMan and
Illumina), and that our study included a larger number of samples
(n=697) than public resources (n=60), we believe our results are
accurate. Such a difference from the expected MAF may be due to
reduced power in HapMap compared to this work or due to
population stratification (i.e. the MAF of 0.09 for Yorubans in
Nigeria could be markedly lower than elsewhere on the continent
from where ancestors of our participants may have lived). More
work into the genetic population structure across Africa and in
admixed populations such as African Americans is needed to
appreciate such differences.
Population-based differences in susceptibility to RA are
observed through previous reports that show an association
Table 6. Minor allele frequencies of CTLA4 SNPs for African American RA patients and controls.
SNP
Minor
Allele Position
CCP+
Patients
CCP2
Patients
SE+
Patients
SE2
Patients
All
Patients Controls
Public Database:
African
Public Database:
European
Fisher’s Exact
P values
rs733168 C 21722 0.134 0.128 0.158 0.113 0.123 0.142 0.15 0.07 0.0113
rs231772 A 21113 0.030 0.031 0.034 0.033 0.028 0.053 0.09 0.00 0.0462
rs231775 G 48 0.424 0.392 0.442 0.381 0.413 0.372 0.42 0.39 0.2827
rs231776 A 184 0.023 0.031 0.034 0.026 0.027 0.038 0.10 0.00 0.0418
rs231777 T 922 0.240 0.232 0.252 0.238 0.244 0.220 0.13 0.27 0.7651
rs231778 G 1155 0.053 0.046 0.063 0.046 0.054 0.209 0.09 0.00 4.462610
226
rs231779 T 1821 0.464 0.448 0.490 0.424 0.460 0.452 0.42 0.38 0.3718
5251* A 2107 0.060 0.041 0.034 0.066 0.045 0.040 0.08 0.00 0.8275
rs231780 G 4031 0.082 0.119 0.102 0.096 0.097 0.124 0.17 0.00 0.0667
rs34031880 C 6222 0.036 0.067 0.054 0.043 0.045 0.063 0.04 0.00 0.2222
rs3087243 A 6253 0.161 0.186 0.170 0.169 0.167 0.195 0.17 0.41 0.6343
rs11571319 A 6272 0.217 0.180 0.199 0.215 0.197 0.141 0.12 0.20 0.0731
This table represents combined data from CLEAR I and CLEAR II. rs3087243 (+60C/T) has been associated with RA in Caucasians, and rs231775 (+49A/G) has been
associated with other autoimmune conditions. Position is the physical location of each polymorphism relative to the start codon (position=0) in dbSNP build 129. CCP
refers to anti-cyclic citrullinated antibody status. SE refers to presence of HLA-DRB1 shared epitope. Public databases include allele frequencies from HapMap or
SeattleSNP. rs231776 was not in Hardy-Weinberg Equilibrium. *5251 is not currently listed in dbSNP as described in the methods.
doi:10.1371/journal.pgen.1000424.t006
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affect the expression levels of soluble CTLA4 protein [35], in
Swedish and North-American populations [14] or a lack of
association at this locus in studies based in Massachusetts or
Northern Ireland [7,13]. We failed to find an association of
rs3087243 in RA among African Americans. Even when
stratifying for a clinical subclassification more strongly associated
with CTLA4 [14] (anti-CCP positivity), we could not reproduce
these results in African Americans. This non-replication finding
may be due to genuine population-specific differences in allele
frequency or different patterns of LD among African and
European ancestry individuals, but our relatively small sample
size precludes definitive conclusions. For example, to detect a
small genetic effect [OR=1.08 (95% CI: 1.01–1.17)] in a meta-
analysis of genotypes, Plenge et al. analyzed ,4,000 Caucasian
RA samples [14], a much higher number of subjects than is
available for our analysis. We also failed to find an association with
the nonsynonymous SNP, rs231775 (+49A/G), which has been
implicated in multiple autoimmune diseases, again possibly due to
small sample size.
CTLA4 is an important molecule in preventing an inappro-
priate immune response and in dampening osteoclast formation
[4], both of which may have implications for the pathogenesis
of RA. CTLA4 stimulation functions in regulatory T cell
development including proliferation and frequency [2,3,36],
providing another possible mechanism for this protein to
influence RA pathogenesis. While we do not address possible
functional consequences of this polymorphism, future work may
reveal a relationship between rs231778 and T cell/osteoclast
development or linkage disequilibrium with a SNP outside of
the CTLA4 gene boundaries that influences expression or
function.
In conclusion, our results suggest a need for greater under-
standing of CTLA4 function and of the ethnic-specific genetic
contributions to RA including relationship to disease pathogenesis.
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